Jennifer M. Oh

Jennifer M. Oh

Auto-generated profile, based on publicly available information

Jennifer M. Oh

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
CEClaire M. Erickson
Claire M. Erickson
SSStephanie A. Schultz
Stephanie A. Schultz
JOJennifer M. Oh
Jennifer M. Oh
BDBurcu F. Darst
Burcu F. Darst
YMYue Ma
Yue Ma
OOOzioma C. Okonkwo
Ozioma C. Okonkwo
Objective To examine whether the KLOTHO gene variant KL-VS attenuates APOE4-associated β-amyloid (Aβ) accumulation in a late-middle-aged cohort enriched with Alzheimer disease (AD) risk factors. Methods Three hundred nine late-middle-aged adults from the Wisconsin Registry for Alzheimer9s Prevention and the Wisconsin Alzheimer9s Disease Research Center were genotyped to determine KL-VS and APOE4 status and underwent CSF sampling (n = 238) and/or 11C-Pittsburgh compound B (PiB)-PET imaging (n = 183). Covariate-adjusted regression analyses were used to investigate whether APOE4 exerted expected effects on Aβ burden. Follow-up regression analyses stratified by KL-VS genotype (i.e., noncarrier vs heterozygous; there were no homozygous individuals) evaluated whether the influence of APOE4 on Aβ was different among KL-VS heterozygotes compared to noncarriers. Results APOE4 carriers exhibited greater Aβ burden than APOE4-negative participants. This effect was stronger in CSF (t = −5.12, p < 0.001) compared with PiB-PET (t = 3.93, p < 0.001). In the stratified analyses, this APOE4 effect on Aβ load was recapitulated among KL-VS noncarriers (CSF: t = −5.09, p < 0.001; PiB-PET: t = 3.77, p < 0 .001). In contrast, among KL-VS heterozygotes, APOE4-positive individuals did not exhibit higher Aβ burden than APOE4-negative individuals (CSF: t = −1.03, p = 0.308; PiB-PET: t = 0.92, p = 0.363). These differential APOE4 effects remained after KL-VS heterozygotes and noncarriers were matched on age and sex. Conclusion In a cohort of at-risk late-middle-aged adults, KL-VS heterozygosity was associated with an abatement of APOE4-associated Aβ aggregation, suggesting KL-VS heterozygosity confers protections against APOE4-linked pathways to disease onset in AD.

6 May 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
GEGilda E. Ennis
Gilda E. Ennis
AKAkshay Kohli
Akshay Kohli
EJErin M. Jonaitis
Erin M. Jonaitis
TBTobey J. Betthauser
Tobey J. Betthauser
JOJennifer M. Oh
Jennifer M. Oh
BBBarbara B. Bendlin
Barbara B. Bendlin